Selective PI3Kδ Inhibitor for Hematological Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematological tumors and autoimmune diseases related to PI3Kδ activity are limited in efficacy and specificity, with potential side effects due to non-selective inhibition of PI3Kδ.
Innovation Solution
A selective PI3Kδ kinase inhibitor, comprising a compound of formula (I) or its pharmaceutically acceptable salts, solvates, esters, acids, metabolites, or prodrugs, which specifically targets PI3Kδ kinase activity without significantly affecting other PI3K family members.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PI3K inhibitors are used, then PI3Kδ activity is inhibited, but other PI3K family members are also affected causing side effects
Solution Approach 1:
The patent applies local quality by designing a inhibitor with specific molecular structure features (formula I) that confer selectivity for PI3Kδ over other PI3K isoforms. The compound contains specific substituents (R1-R6) and structural elements (X, Y, Z) that enable selective binding to PI3Kδ's unique structural characteristics, particularly its p110δ catalytic subunit, while avoiding interaction with PI3Kα, β, and γ isoforms.
Solution Approach 2:
The patent employs parameter changes by optimizing specific molecular parameters of the inhibitor compound, including the identity and position of substituents R1 through R6, the stereochemistry (R/S configurations), and the structural parameters of rings A, B, and C. These parameter optimizations enable the compound to achieve high selectivity for PI3Kδ, demonstrating inhibition ratios greater than 100-fold over other PI3K isoforms in certain embodiments.
2Measurement precision
If selective PI3Kδ inhibitors are developed, then specificity is improved, but treatment efficacy for related diseases needs to be maintained
Solution Approach 1:
The patent maintains therapeutic efficacy through local quality by incorporating specific functional groups and structural motifs in formula (I) that are essential for PI3Kδ binding and inhibition. The compound retains key pharmacophoric elements necessary for blocking PI3Kδ's catalytic activity, including the ATP-competitive binding mode and specific interactions with residues in the PI3Kδ active site, ensuring potent inhibition (IC50 values in the nanomolar range) while achieving selectivity.
Solution Approach 2:
The patent uses the inhibitor compound as an intermediary that selectively mediates the blocking of PI3Kδ signaling pathways involved in hematological tumors and autoimmune diseases. The compound acts as a precise mediator that interrupts disease-related signaling cascades (such as those involving B cells, T cells, and inflammatory responses) without disrupting other PI3K-mediated physiological processes, thereby maintaining therapeutic efficacy while achieving specificity.
Data Source
AI summary
The present application relates to a compound serving as a selective PI3Kδ kinase inhibitor, comprising the compound shown in formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof, wherein X, R1, R2, R3, R4, R5 and R6 are as defined in the description. The present application also relates to a method for using the kinase inhibitor to inhibit PI3Kδ kinase activity or to treat or prevent diseases or conditions associated with tyrosine kinase activity of PI3Kδ, as well as a use thereof.